Key Insights on Gross Profit: Dr. Reddy's Laboratories Limited vs Catalent, Inc.

Pharma Giants' Profit Battle: Dr. Reddy's vs. Catalent

__timestampCatalent, Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 201459860000075801000000
Thursday, January 1, 201561530000085403000000
Friday, January 1, 201658760000092281000000
Sunday, January 1, 201765460000078356000000
Monday, January 1, 201875260000076304000000
Tuesday, January 1, 201980510000083430000000
Wednesday, January 1, 202098330000094009000000
Friday, January 1, 20211352000000103077000000
Saturday, January 1, 20221640000000113840000000
Sunday, January 1, 20231060000000202972000000
Monday, January 1, 2024953000000163607000000
Loading chart...

Cracking the code

A Decade of Gross Profit: Dr. Reddy's Laboratories vs. Catalent, Inc.

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. Over the past decade, Dr. Reddy's Laboratories Limited and Catalent, Inc. have showcased distinct trajectories in gross profit. Dr. Reddy's Laboratories, a prominent player in the global pharmaceutical market, has consistently outperformed Catalent, Inc., with gross profits peaking at over 200% higher in 2023 compared to Catalent. This trend highlights Dr. Reddy's robust market presence and strategic growth.

Catalent, Inc., while trailing behind, has shown a commendable upward trend, with a 64% increase in gross profit from 2014 to 2022. This growth reflects Catalent's expanding role in drug development and delivery solutions. The data from 2014 to 2024 provides a compelling narrative of how these two companies have navigated the competitive landscape, offering insights into their financial strategies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025